gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · CRMDHealthcarePharmaceuticals

CorMedix Inc. (CRMD)

$5.66+1.80%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$5.66▼ 50.44% in range
Nov 4, 2025Low $5.39 · High $12.73Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

CorMedix closed at $5.66 on Nov 4, up 1.80%, 55.5% below its 52-week closing high. Volume of 1.5M shares was 0.90× its 20-day average (close to normal).

Split-adjusted performance: -22.3% over one month, -29.7% over six months, -51.0% over one year.

In the quarter ended Jun 30, 2026, revenue was $101.93M, up 156.5% from a year earlier, with a net margin of 25.5%.

Short interest was 14.7M shares at the Oct 15 settlement, down 4.9% from the prior report (20.8% of float, 12.7 days to cover).

Market cap$441.2M77.9M shares
Revenue · quarter$101.9M+156.5% YoY
Diluted EPS$0.29+3.6% YoY
P/E · TTM2.4×P/S 1.0×
Net margin25.5%Gross 75.7%
Dividend yieldNone
52-week range5.39 – 12.73−55.5% from high
Volume1.5M0.90× 20-day avg
Volatility · 60d77.3%Annualised
Short % of float20.8%12.7 days to cover
Net cash$256.7MCash $256.7M
Next earnings—Not scheduled
Split-adjusted performance
1W −31.0%1M −22.3%3M −24.6%6M −29.7%YTD −51.3%1Y −51.0%3Y +77.4%5Y +14.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum45
Revenue growth87
Net margin87
Value (low P/E)95
Size59

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short14.7M−4.9% vs prior
Days to cover12.7Settled Oct 15
% of float20.8%
Short vol. 10d64.9%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
CRMDCorMedix$5.66+1.80%−29.7%+156.5%25.5%2.4$441.2M
INDPIndaptus Therapeutics$3.30+1.85%+61.0%———$439.7MCompare
RLMDRelmada Therapeutics$4.17−2.34%−46.9%———$444.8MCompare
TLRYTilray Brands$2.96+11.70%−48.6%+22.7%−16.8%—$437.5MCompare
PRTAProthena$8.39+2.19%−25.0%−77.1%−1839.9%—$430.7MCompare
PHATPhathom Pharmaceuticals$5.68−1.05%−55.2%+71.1%−16.4%—$461.7MCompare
GYREGyre Therapeutics$4.440.00%−44.8%−2.1%−40.1%—$470.8MCompare
ALTAltimmune$2.12+3.92%−35.0%−100.0%——$412.4MCompare
AQSTAquestive Therapeutics$3.80−2.06%−10.2%+38.1%−165.5%—$476.9MCompare

News about CorMedix

All news →
Earnings Preview: CorMedix (CRMD) Q3 Earnings Expected to DeclineZacks Investment Research · 17h ago▼ NegativeCRMD vs. PRTA: Which Stock Should Value Investors Buy Now?Zacks Investment Research · Oct 8, 2026▲ Positive

Quick answers

What does CorMedix do?
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets.
What is CRMD's market cap?
$441.16M, based on the Nov 4 close of $5.66.
What is CRMD's P/E ratio?
2.4× trailing-twelve-month earnings of $187.18M.
Does CorMedix pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CRMD is sold short?
14.7M shares, 20.8% of float, as of Oct 15, 2026.
What sector is CRMD in?
Healthcare, in the Pharmaceuticals industry.

About CorMedix

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

HQ: Parsippany, NJ191 employeesListed May 13, 2010cormedix.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology